Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | (447.8%) | 0.0% | 192.6% | 41.5% | 28.8% | 20.4% | 16.3% | (925.8%) | 390.1% | (859.4%) | (31.4%) | (47.4%) | (20.1%) | (169.3%) | (36.0%) | (53.0%) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is (90.1%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for Aadi Bioscience, Inc. have been (61.9%) over the past three years, and (59.1%) over the past five years.
As of today, Aadi Bioscience, Inc.'s Return on Capital Employed (ROCE) is (90.1%), which is lower than industry median of (51.0%). It indicates that Aadi Bioscience, Inc.'s Return on Capital Employed (ROCE) is Bad.